There are believed to be more than 1 million individuals worldwide currently with an organ allograft , and a further steep increase in numbers is expected in the next decade. The life-enhancing benefits of organ transplantation are undisputed, but come at a cost. Complications from graft-preserving iatrogenic immunosuppression include a significantly increased risk of malignancy. More than 40 primary malignant neoplasms were reported in the first 4,000 patients to undergo renal transplantation , and this early observation has been consistently supported by subsequent studies [3-7].
|Title of host publication||Cancer Treatment and Research|
|Number of pages||21|
|Publication status||Published - 1 Jan 2009|